The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Henry Schein beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly and GAAP earnings per share improved.
Gross margins shrank, operating margins were steady, net margins dropped.
Henry Schein tallied revenue of $2.34 billion. The 12 analysts polled by S&P Capital IQ expected sales of $2.22 billion on the same basis. GAAP reported sales were 16% higher than the prior-year quarter's $2.02 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.15. The 16 earnings estimates compiled by S&P Capital IQ anticipated $1.12 per share. GAAP EPS of $1.15 for Q4 were 15% higher than the prior-year quarter's $1.00 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 27.9%, 50 basis points worse than the prior-year quarter. Operating margin was 7.0%, about the same as the prior-year quarter. Net margin was 4.5%, 10 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $2.04 billion. On the bottom line, the average EPS estimate is $0.91.
Next year's average estimate for revenue is $8.78 billion. The average EPS estimate is $4.32.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 92 members out of 100 rating the stock outperform, and eight members rating it underperform. Among 32 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 31 give Henry Schein a green thumbs-up, and one gives it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Henry Schein is hold, with an average price target of $71.82.
If you're interested in health-care stocks like Henry Schein, you might want to expand your horizons to find maximum returns. Follow the money and meet a prime candidate for major returns in our new report, "Discover the Next Rule-Breaking Multibagger." Click here for instant access to this free report.
- Add Henry Schein to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Henry Schein, Inc. Is Falling
Shares tumbled after the company reported disappointing third-quarter earnings.
The 3 Best Dental Stocks to Buy in 2017
These companies could put smiles on investors' faces for years to come.
Stocks to Watch in Dental Products: Henry Schein Inc. and Sirona Dental Systems Inc.
Should you fill the cavities in your portfolio with these two dental stocks?